First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
Explore the data across all severities, including 5 years of moderate to severe plaque psoriasis data and multiple endpoints in special areas like scalp and nail 2,*
*Moderate to severe plaque psoriasis patients in the ESTEEM clinical trials could be treated through 5 years.
The safety profile for Otezla was studied in 6 clinical trials in both mild to moderate and moderate to severe plaque psoriasis 1,4,‡
†Moderate to severe plaque psoriasis patients in the ESTEEM clinical trials could be treated through 5 years. ‡The 6 clinical trials include ADVANCE, ESTEEM 1 & 2, STYLE, LIBERATE, and DISCREET. §Estimates of patients treated reflect global data since launch (Apr 2014-Mar 2023; US=58% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
Inclusion on formulary does not imply superior clinical efficacy or safety.
BSA=body surface area.
**Covered includes Covered, Covered (PA/ST), Preferred and Preferred (PA/ST) as defined by Managed Markets Insights and Technology (MMIT) data.
††Number of commercially insured plaque psoriasis lives provided is obtained from MMIT for health plans in the US. Data as of April 2023.
‡‡Number of commercially insured plaque psoriasis and active psoriatic arthritis lives provided is obtained from MMIT for health plans in the US. Data as of June 2023.
§§86% of commercially insured patients have access to Otezla with no step edits after trying topicals for plaque psoriasis.
***Includes disease-modifying antirheumatic drug (DMARD) and bio step.
MOA, mechanism of action; MOD, mode of disease.
ContraindicationsOtezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation
Warnings and PrecautionsHypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
Warnings and Precautions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Van Voorhees A, Feldman S, Lebwohl M, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide. psoriasis.org/the-pocket-guide. Accessed August 27, 2023. 4. Reich K, Gooderham M, Green L, et al. J Eur Acad Dermatol Venereol. 2017;31(3):507-517. 5. Otezla® (apremilast) FDA approval letter. March 21, 2014.